Patten DK, Schultz BG, Berlau DJ
Orforglipron In phase II, randomized, double-blind study, adults with overweight or obesity and without T2DM who took oral orforglipron (12, 24, 36, or 45 mg) daily for 36 weeks experienced a weight reduction of 9.414.7% [105]
No reason to expect significant rebound or withdrawal
AOD 9604 does not interact with growth hormone receptors, does not affect insulin signaling, and does not cross into the central nervous system to alter appetite or mood
Growth Hormone and Testosterone Interaction Research published in the Journal of Clinical Investigation demonstrated that GH and testosterone have additive effects on body composition
Is the research-grade BPC-157 peptide legal to purchase in Canada